$39.1 Million is the total value of CAXTON CORP's 17 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SVRA | SAVARA INC | $10,689,654 | -0.0% | 6,896,551 | 0.0% | 27.30% | +35.8% | |
| XERIS BIOPHARMA HOLDINGS INC | $8,031,907 | -14.7% | 6,039,028 | 0.0% | 20.52% | +15.8% | ||
| SPY | SPDR S&P 500 ETF TRtr unit | $6,098,611 | +7.1% | 15,947 | 0.0% | 15.58% | +45.4% | |
| RZLT | REZOLUTE INC | $2,904,535 | -24.5% | 1,403,157 | 0.0% | 7.42% | +2.6% | |
| SCYX | SCYNEXIS INC | $2,689,357 | -35.0% | 1,723,947 | 0.0% | 6.87% | -11.7% | |
| XOP | SPDR SER TRs&p oilgas exp | $2,377,900 | +8.9% | 17,500 | 0.0% | 6.07% | +48.0% | |
| AMLP | ALPS ETF TRalerian mlp | $1,123,065 | +4.1% | 29,500 | 0.0% | 2.87% | +41.4% | |
| MTEM | MOLECULAR TEMPLATES INC | $673,381 | -56.2% | 2,052,991 | 0.0% | 1.72% | -40.6% | |
| BTWNW | BRIDGETOWN HOLDINGS LTD*w exp 09/30/202 | $4,671 | -6.6% | 39,773 | 0.0% | 0.01% | +33.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.